WebJul 15, 2024 · China Oncology Focus, a subsidiary of Lee’s Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with chemotherapy as a first-line treatment of extensive-stage small-cell lung cancer. Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. WebFeb 18, 2024 · News in Focus. Browse All News Multimedia Gallery Trending Topics Business & Money. Auto & Transportation ... China Oncology Drugs Market size was US$ 23.70 billion in 2024.
Chinese solar panels: Are they any good? (2024)
WebApr 13, 2024 · ATMPs should be the first area of focus for regulatory harmonization, conference attendees agreed. Already, some drug regulators have teamed up for early conversations with companies—for example, the ACCESS Consortium and Project Orbis allows different drug regulators and companies to connect and align for simultaneous … Web14 hours ago · The panelist session is titled China @ AACR and will focus on China's international cooperation in cancer research. ... with China leading in the region. … north african fruits
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti …
WebOct 7, 2014 · M2 PHARMA-October 7, 2014-China Oncology Focus receives license for STI-A1014 from Sorrento Therapeutics (C)2014 M2 COMMUNICATIONS China Oncology Focus, an affiliate of Lee's Pharma, has received a license for its fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014 from United … WebFeb 9, 2024 · HONG KONGand SAN DIEGO, Feb. 09, 2024(GLOBE NEWSWIRE) -- China Oncology Focus Limited(COF), an affiliate of Lee's Pharmaceutical Holdings Limited(Lee's Pharma, HKEX: 950), and Sorrento Therapeutics, Inc.(Sorrento, Nasdaq: SRNE), today announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for … north african genetics